In vitro leukemia cell models of Ara-C resistance

被引:24
作者
Funato, T
Satou, J
Nishiyama, Y
Fujimaki, S
Miura, T
Kaku, M
Sasaki, T
机构
[1] Tohoku Univ, Sch Med, Dept Mol Genet, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Sch Med, Dept Rheumatol & Hematol, Aoba Ku, Sendai, Miyagi 9808574, Japan
关键词
cytosine arabinoside (Ara-C); deoxycytidine kinase (dCK); human leukemia K562 cell; antisense oligonucleotides; drug resistance;
D O I
10.1016/S0145-2126(00)00016-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cells of the human leukemia line K562 were continuously exposed to cytosine arabinoside (Ara-C) at increasing concentrations for 3 months. The resulting cell line, termed K562/AC, showed 48-fold resistance to Ara-C, compared with the parental K562 cells. The sensitivities of K562/AC to adriamycin (ADR), vincristine (VCR) and etoposide (VP16) were similar to those of parental K562. Gene analysis revealed that this cell line lacked expression of the deoxycytidine kinase (dCK) gene, which was evident in Ara-C-sensitive cells. As in K562 cells, multidrug resistance (MDR-1) and multidrug resistance protein (MRP) genes were not expressed in K562/AC. We also established an in vitro model of Ara-C resistance using phosphorothioate antisense oligonucleotides to dCK (dCK-AS). Treatment of K562 with dCK-AS caused decreased dCK expression and 6- to 10-fold increases in resistance to Ara-C, compared with that in cells treated with sense oligonucleotides to dCK (dCK-S) or in non-transfected cells. The cells described here may contribute to the study of a novel mechanism associated with Ara-C resistance, in which reduced dCK activity may play an important role. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:535 / 541
页数:7
相关论文
共 26 条
[1]   P-GLYCOPROTEIN AND TUMOR PROGRESSION [J].
BENCHIMOL, S ;
LING, V .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :814-816
[2]   CLONING AND EXPRESSION OF HUMAN DEOXYCYTIDINE KINASE CDNA [J].
CHOTTINER, EG ;
SHEWACH, DS ;
DATTA, NS ;
ASHCRAFT, E ;
GRIBBIN, D ;
GINSBURG, D ;
FOX, IH ;
MITCHELL, BS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1531-1535
[3]  
FLASSHOVE M, 1994, LEUKEMIA, V8, P780
[4]   Multi-drug resistance in chronic lymphocytic leukemia [J].
Friedenberg, WR ;
Spencer, SK ;
Musser, C ;
Hogan, TF ;
Rodvold, KA ;
Rushing, DA ;
Mazza, JJ ;
Tewksbury, DA ;
Marx, JJ .
LEUKEMIA & LYMPHOMA, 1999, 34 (1-2) :171-178
[5]   Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines [J].
Fukuda, T ;
Kamishima, T ;
Kakihara, T ;
Ohnishi, Y ;
Suzuki, T .
LEUKEMIA RESEARCH, 1996, 20 (11-12) :931-939
[6]  
Funato T, 1997, IN VIVO, V11, P217
[7]  
FUNATO T, 1992, ADV ENZYME REGUL, V32, P195
[8]  
FUQUA SAW, 1990, BIOTECHNIQUES, V9, P206
[9]  
Grant S, 1998, ADV CANCER RES, V72, P197
[10]   WT1 AS A NEW PROGNOSTIC FACTOR AND A NEW MARKER FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA [J].
INOUE, K ;
SUGIYAMA, H ;
OGAWA, H ;
NAKAGAWA, M ;
YAMAGAMI, T ;
MIWA, H ;
KITA, K ;
HIRAOKA, A ;
MASAOKA, T ;
NASU, K ;
KYO, T ;
DOHY, H ;
NAKAUCHI, H ;
ISHIDATE, T ;
AKIYAMA, T ;
KISHIMOTO, T .
BLOOD, 1994, 84 (09) :3071-3079